Scopus BioPharma

Scopus BioPharma is a biotechnology company established in 2018 and based in New York, focusing on the development of small molecule therapeutics that target the endocannabinoid system. The company specializes in synthetically-produced cannabinoids, which interact with cannabinoid receptors throughout the body. Its product candidates include CO-sTiRNA, a gene therapy designed to inhibit the STAT3 pathway, and MRI-1867, a therapeutic candidate aimed at addressing various medical conditions. Through its innovative approach, Scopus BioPharma aims to leverage the therapeutic potential of cannabinoids for diverse health applications.